Can you help me interpret the DEXA scan results for a 57-year-old female with lumbar spine T-score of –2.2, total hip T-score of –2.0, femoral neck T-score of –2.5, distal one‑third radius T-score of –1.5, and 10‑year FRAX probabilities of 8.4% for a major osteoporotic fracture and 1.6% for a hip fracture?

DEXA Scan Interpretation for 57-Year-Old Female

This patient has osteoporosis at the femoral neck (T-score –2.5) and should be offered pharmacologic treatment with a bisphosphonate as first-line therapy, along with calcium 1,200 mg daily and vitamin D 600 IU daily. 1

Diagnostic Classification

Your patient meets WHO criteria for osteoporosis based on the femoral neck T-score of –2.5, which is at the diagnostic threshold. 1 The diagnosis is confirmed when any of the following sites (lumbar spine, femoral neck, or total hip) has a T-score ≤ –2.5. 1

Site-by-Site Analysis:

• Femoral neck (–2.5): Osteoporosis 1
• Total hip (–2.0): Osteopenia (between –1.0 and –2.5) 1
• Lumbar spine (–2.2): Osteopenia 1
• Distal 1/3 radius (–1.5): Osteopenia 1

The femoral neck is the WHO-recommended reference site for diagnosis, making this the most clinically significant measurement. 1

Fracture Risk Assessment

The FRAX scores indicate this patient does NOT meet the treatment threshold based on fracture probability alone, but treatment is still indicated because of the osteoporotic T-score. 1

FRAX Score Interpretation:

• 10-year major osteoporotic fracture risk: 8.4% (threshold for treatment is ≥20%) 1
• 10-year hip fracture risk: 1.6% (threshold for treatment is ≥3%) 1

Important caveat: While the FRAX scores are below treatment thresholds, the presence of a T-score ≤ –2.5 automatically qualifies this patient for pharmacologic treatment regardless of FRAX results. 1 Treatment is recommended in women with a T-score of –2.5 or less, independent of fracture risk calculation. 1

Treatment Recommendations

Non-Pharmacologic Interventions (Mandatory for All Patients):

Calcium and Vitamin D supplementation:

• Calcium: 1,200 mg daily (for women 51-70 years) 1
• Vitamin D: 600 IU daily minimum (for women 51-70 years), though doses up to 800-1,000 IU daily are recommended for bone health 1
• Target serum vitamin D level ≥20 ng/mL 1

Lifestyle modifications:

• Weight-bearing exercise (walking, jogging) at least 30 minutes, 3 days per week 1
• Balance training and resistance exercises to reduce fall risk 1
• Smoking cessation 1
• Limit alcohol consumption 1

Pharmacologic Treatment:

First-line therapy: Oral bisphosphonates (alendronate or risedronate) based on patient preference. 1

Dosing options for alendronate:

• 10 mg daily OR 70 mg weekly 1
• Alendronate/cholecalciferol combination (70 mg plus 2,800-5,600 IU vitamin D weekly) 1

Dosing options for risedronate:

• 5 mg daily, 35 mg weekly, 75 mg on two consecutive days per month, or 150 mg monthly 1

Alternative agents if bisphosphonates are contraindicated or not tolerated:

• Denosumab (subcutaneous) for high fracture risk 1
• Raloxifene may be appropriate for younger postmenopausal women 1
• Teriparatide reserved for severe osteoporosis or those with fractures 1

Critical Administration Instructions for Oral Bisphosphonates:

Contraindications to monitor:

• Esophageal abnormalities 1
• Inability to stand or sit upright for at least 30 minutes after dosing 1
• Hypocalcemia (must be corrected before starting) 1

Follow-Up Monitoring

Repeat DEXA scanning should be performed every 2 years to assess treatment response, though testing should generally not be conducted more frequently than annually. 1 More frequent monitoring may be warranted if bone loss is expected to be rapid or if adherence is uncertain. 1

Clinical Pearls and Pitfalls

Common pitfall: The distal radius T-score of –1.5 is often overlooked, but recent evidence suggests distal forearm DEXA may better predict distal radius fractures in elderly females than central DEXA alone. 2 While not changing the diagnosis here, this measurement provides additional fracture risk information for this specific site.

Important consideration: Approximately 70% of hip fractures can be predicted if DXA scanning is performed regularly, emphasizing the value of ongoing monitoring. 3 However, most fragility fractures occur in persons without osteoporosis (T-scores >–2.5), which is why the combination of BMD measurement and clinical risk assessment is crucial. 1

Treatment urgency: With a T-score at the osteoporotic threshold and the patient being only 57 years old, early intervention is critical to prevent future fractures and preserve quality of life over her remaining decades. 1 Bisphosphonates have been shown to reduce hip fracture risk by approximately 36% and vertebral fractures by 54-68% over 3 years. 1